Alloimmunity and autoimmunity in chronic rejection

Current Opinion in Organ Transplantation

Volumn 15, Issue 4, 2010, Pages 531-536

  Seetharam, Anil ^a   Tiriveedhi, Venkataswarup ^b   Mohanakumar, T ^b,c  

^a Division of Gastroenterology   (United States)

^b Department of Surgery ^*  (Australia)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

alloimmunity; antibody mediated rejection; autoimmunity; chronic rejection; organ transplantation

Indexed keywords

FIBRINOGEN; HLA ANTIGEN CLASS 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; AUTACOID;

ALLOIMMUNITY; AUTOIMMUNITY; BRONCHIOLITIS OBLITERANS; CARDIAC ALLOGRAFT VASCULOPATHY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL SURFACE; CELLULAR IMMUNITY; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GRAFT REJECTION; DENDRITIC CELL; FIBROGENESIS; GLOMERULOPATHY; GRAFT FAILURE; HEART TRANSPLANTATION; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; REVIEW; TRANSPLANTATION TOLERANCE; VASCULAR DISEASE; ALLOTRANSPLANTATION; ANIMAL; CHRONIC DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; ORGAN TRANSPLANTATION; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; AUTOIMMUNITY; CHRONIC DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOSUPPRESSION; INFLAMMATION MEDIATORS; ORGAN TRANSPLANTATION; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77955230191     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833b31f4     Document Type: Review

References (46)

1. Tiriveedhi V, Weber J, Seetharam A, Mohanakumar T. Cross-talk of alloimmune response and autoimmunity: role in pathogenesis of chronic rejection. Discov Med Mar; 9:229-235.
2. Nicod LP. Mechanisms of airway obliteration after lung transplantation. Proc Am Thorac Soc 2006; 3:444-449.
3. Nath DS, Basha HI, Mohanakumar T. Antihuman leukocyte antigen antibodyinduced autoimmunity: role in chronic rejection. Curr Opin Organ Transplant Feb; 15:16-20.
4. Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. Transpl Immunol 2002; 10 (2-3):101-108.
5. Hernandez-Fuentes MP, Baker RJ, Lechler RI. The alloresponse. Rev Immunogenet 1999; 1:282-296.
6. Bharat A, Mohanakumar T. Allopeptides and the alloimmune response. Cell Immunol 2007; 248:31-43.
7. Shilling RA, Wilkes DS. Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond. Am J Transplant 2009; 9:1714-1718.
8. Hachem RR. Lung allograft rejection: diagnosis and management. Curr Opin Organ Transplant 2009; 14:477-482.
9. Heeger PS. T-cell allorecognition and transplant rejection: a summary and update. Am J Transplant 2003; 3:525-533.
10. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999; 162:352-358.
11. Suchin EJ, Langmuir PB, Palmer E, et al. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001; 166:973-981.
12. Sawyer GJ, Dalchau R, Fabre JW. Indirect T cell allorecognition: a cyclosporin A resistant pathway for T cell help for antibody production to donor MHC antigens. Transpl Immunol 1993; 1:77-81.
13. Stastny P, Ring S, Lu C, et al. Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients. Hum Immunol 2009; 70:600-604.
14. Goers TA, Ramachandran S, Aloush A, et al. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol 2008; 180:4487-4494.
15. Iwata T, Philipovskiy A, Fisher AJ, et al. Antitype V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008; 181:5738-5747.
16. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007; 117:3498-3506.
17. Huang HJ, Yusen RD, Meyers BF, et al. Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome. Am J Transplant 2008; 8:2454-2462.
18. Suciu-Foca N, Reed E, Marboe C, et al. The role of anti-HLA antibodies in heart transplantation. Transplantation 1991; 51:716-724.
19. Suciu-Foca N, Reed E, D'Agati VD, et al. Soluble HLA antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients. Transplantation 1991; 51:593-601.
20. Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88:568-574.
21. Weis M, von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 1997; 96:2069-2077.
22. Jindra PT, Hsueh A, Hong L, et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol 2008; 180:2214-2224.
23. Brennan TV, Hoang V, Garrod KR, et al. A new T-cell receptor transgenic model of the CD4+ direct pathway: level of priming determines acute versus chronic rejection. Transplantation 2008; 85:247-255.
24. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008; 205:3133-3144.
25. Kaczmarek I, Deutsch MA, Kauke T, et al. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant 2008; 6:229-235.
26. Rose ML, Smith JD. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol 2009; 70:605-609.
27. Atz ME, Reed EF. Role of anti-MHC class I antibody in facilitating transplant accommodation. Crit Rev Immunol 2008; 28:485-511.
28. Leong HS, Mahesh BM, Day JR, et al. Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor. J Leukoc Biol 2008; 83:263-271.
29. Smith CR, Jaramillo A, Duffy BF, Mohanakumar T. Airway epithelial cell damage mediated by antigen-specific T cells: implications in lung allograft rejection. Hum Immunol 2000; 61:985-992.
30. Bharat A, Narayanan K, Street T, et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation 2007; 83:150-158.
31. Sato M, Hirayama S, Hwang DM, et al. The role of intrapulmonary de novo lymphoid tissue in obliterative bronchiolitis after lung transplantation. J Immunol 2009; 182:7307-7316.
32. Haque MA, Mizobuchi T, Yasufuku K, et al. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol 2002; 169:1542-1549.
33. Bharat A, Fields RC, Steward N, et al. CD4+25+ regulatory T cells limit Th1- autoimmunity by inducing IL-10 producing T cells following human lung transplantation. Am J Transplant 2006; 6:1799-1808.
34. Jaramillo A, Smith MA, Phelan D, et al. Development of ELISA-detected anti- HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999; 67:1155-1161.
35. Rizzo M, Sundaresan S, Lynch J, et al. Increased concentration of soluble human leukocyte antigen class I levels in the bronchoalveolar lavage of human pulmonary allografts. J Heart Lung Transplant 1997; 16:1135-1140.
36. Fukami N, Ramachandran S, Saini D, et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol 2009; 182:309-318.
37. Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007; 175:507-513.
38. Schirren CA, Jung MC, Gerlach JT, et al. Liver-derived hepatitis C virus (HCV)- specific CD4+ T cells recognize multiple HCV epitopes and produce interferon gamma. Hepatology 2000; 32:597-603.
39. Bharat A, Barros F, Narayanan K, et al. Characterization of virus-specific T-cell immunity in liver allograft recipients with HCV-induced cirrhosis. Am J Transplant 2008; 8:1214-1220.
40. Hsu HC, Yang P, Wang J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008; 9:166-175.
41. Hertig A, Anglicheau D, Verine J, et al. Early epithelial phenotypic changes predict graft fibrosis. J Am Soc Nephrol 2008; 19:1584-1591.
42. Birnbaum LM, Lipman M, Paraskevas S, et al. Management of chronic allograft nephropathy: a systematic review. Clin J Am Soc Nephrol 2009; 4:860-865.
43. Li C, Yang CW. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 2009; 5:513-519.
44. Fotheringham J, Angel CA, McKane W. Transplant glomerulopathy: morphology, associations and mechanism. Nephron Clin Pract 2009; 113:c1-c7; discussion c.
45. Li F, Atz ME, Reed EF. Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways. Curr Opin Immunol 2009; 21:557-562.
46. Bharat A, Fields RC, Mohanakumar T. Regulatory T cell-mediated transplantation tolerance. Immunol Res 2005; 33:195-212.